Enfermedad mínima residual por citometría de flujo en pacientes con leucemia linfoblástica aguda

Instituto Nacional de Salud. Comportamiento epidemiológico de cáncer en menores de 18 años , periodo 2015 a 2020 , Colombia [Internet]. Boletín Epidemiologico Semanal. 2021. Available from: https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2021_Boletin_epidemiologico_semana_5.pdf

Villalba Toquica C del P, Martínez Silva PA, Acero H. Caracterización clínico-epidemiológica de los pacientes pediátricos con leucemias agudas en la Clínica Universitaria Colombia. Serie de casos 2011-2014. Pediatria (Santiago) [Internet]. 2016;49(1):17–22. Available from: http://dx.doi.org/10.1016/j.rcpe.2016.01.002

Gacha Garay MJ, Akle V, Enciso L, Garavito Aguilar ZV. La leucemia linfoblástica aguda y modelos animales alternativos para su estudio en Colombia. Rev Colomb Cancerol [Internet]. 2017;21(4):212–24. Available from: https://www.revistacancercol.org/index.php/cancer/article/view/182

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood [Internet]. 2016;127(20):2391– 405. Available from: https://ashpublications.org/blood/article/127/20/2391/35255/The-2016-revision-to-the-World-Health-Organization

Grimwade LF, Fuller KA, Erber WN. Applications of imaging flow cytometry in the diagnostic assessment of acute leukaemia. Methods [Internet]. 2017;112:39– 45. Available from: http://dx.doi.org/10.1016/j.ymeth.2016.06.023

Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis. JAMA Oncol [Internet]. 2017;3(7):1–9. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2626509

Moorman A V. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica [Internet]. 2016 Apr;101(4):407–16. Available from: http://www.haematologica.org/lookup/doi/10.3324/haematol.2015.141101

Sabath DE. Minimal Residual Disease. Leuk Lymphoma Soc [Internet]. 2018;(35). Available from: https://www. lls.org/sites/default/files/National/USA/Pdf/Publications/FS35_MRD_Final_2019.pdf

Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia:a comprehensive review and 2017 update. Blood Cancer J [Internet]. 2017;7(6):e577. Available from: https://www.nature.com/articles/bcj201753

Tan SH, Bertulfo FC, Sanda T. Leukemia-initiating cellsin T-cell acute lymphoblastic leukemia. Front Oncol [Internet]. 2017;7(SEP). Available from: https://www.frontiersin.org/articles/10.3389/fonc.2017.00218/full

Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects. Front Oncol [Internet]. 2020;10(February):1–11. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2020.00273/full

Genescà E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, et al. Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. Haematologica [Internet]. 2020 Jun;105(6):e294–7. Available from: https://haematologica.org/article/view/9459

Heikamp EB, Pui C-H. Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr [Internet]. 2018 Dec;203:14-24.e2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022347618309442 Sentís I, Gonzalez S, Genescà E, García-Hernández V, Muiños F, Gonzalez C, et al. The evolution of relapse of adult T cell acute lymphoblastic leukemia. Genome Biol [Internet]. 2020;21(1):1–24. Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02192-z

Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol [Internet]. 2017;35(9):975–83. Available from: https://ascopubs.org/doi/10.1200/JCO.2016.70.7836

Van Dongen JJM, Van Der Velden VHJ, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood [Internet]. 2015;125(26):3996–4009. Available from: https://ashpublications.org/blood/article/125/26/3996/34323/ Minimal-residual-disease-diagnostics-in-acute

Wu J, Jia S, Wang C, Zhang W, Liu S, Zeng X, et al. Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing. Front Immunol [Internet]. 2016 Oct 4;7(October):1–11. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2016.00403

Del Principe MI, De Bellis E, Gurnari C, Buzzati E, Savi A, Consalvo MAI, et al. Applications and efficiency of flow cytometry for leukemia diagnostics. Expert Rev Mol Diagn [Internet]. 2019;19(12):1089–97. Available from: https://doi.org/10.1080/14737159.2019.1691918

Azad A, Rajwa B, Pothen A. Immunophenotype discovery, hierarchical organization, and template-based classification of flow cytometry samples. Front Oncol [Internet]. 2016;6(AUG):1–20. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2016.00188/full

Adan A, Alizada G, Kiraz Y, Baran Y, Nalbant A. Flow cytometry: basic principles and applications. Crit Rev Biotechnol [Internet]. 2017;37(2):163–76. Available from: https://www.tandfonline.com/doi/full/10.3109/07388551.2015.1128876

Tembhare P, Badrinath Y, Ghogale S, Patkar N, Dhole N,

Dalavi P, et al. A novel and easy FxCycleTM violet based

flow cytometric method for simultaneous assessment

of DNA ploidy and six-color immunophenotyping.

Cytom Part A [Internet]. 2016;89(3):281–91. Available

from: https://onlinelibrary.wiley.com/doi/full/10.1002/

cyto.a.22803

Kalina T, Lundsten K, Engel P. Relevance of Antibody

Validation for Flow Cytometry. Cytom Part A [Internet].

;97(2):126–36. Available from: https://onlinelibrary.

wiley.com/doi/full/10.1002/cyto.a.23895

Belver L, Ferrando A. The genetics and mechanisms of

T cell acute lymphoblastic leukaemia. Nat Rev Cancer

[Internet]. 2016;16(8):494–507. Available from: http://

dx.doi.org/10.1038/nrc.2016.63

DiGiuseppe JA, Wood BL. Applications of Flow Cytometric

Immunophenotyping in the Diagnosis and Posttreatment

Monitoring of B and T Lymphoblastic Leukemia/

Lymphoma. Cytom Part B - Clin Cytom [Internet].

;96(4):256–65. Available from: https://onlinelibrary.

wiley.com/doi/epdf/10.1002/cyto.b.21833

Dong M, Zhang X, Yang Z, Wu S, Ma M, Li Z, et

al. Patients over 40 years old with precursor T-cell

lymphoblastic lymphoma have different prognostic

factors comparing to the youngers. Sci Rep [Internet].

;8(1):1–7. Available from: https://www.nature.com/

articles/s41598-018-19565-x

Sun J, Wang L, Liu Q, Tárnok A, Su X. Deep learningbased

light scattering microfluidic cytometry for label-free

acute lymphocytic leukemia classification. Biomed Opt

Express [Internet]. 2020;11(11):6674. Available from:

https://www.osapublishing.org/boe/fulltext.cfm?uri=boe-

-11-6674&id=441886

Loghavi S, Kutok JL, Jorgensen JL. B-acute lymphoblastic

leukemia/lymphoblastic lymphoma. Am J Clin Pathol

[Internet]. 2015;144(3):393–410. Available from: https://

academic.oup.com/ajcp/article/144/3/393/1760791

Noronha EP, Codeço Marques LV, Andrade FG, Santos

Thuler LC, Terra-Granado E, Pombo-De-Oliveira MS. The

profile of immunophenotype and genotype aberrations in

subsets of pediatric T-cell acute lymphoblastic leukemia.

Front Oncol [Internet]. 2019;9(APR):1–10. Available

from: https://www.frontiersin.org/articles/10.3389/

fonc.2019.00316/full

Rocha JMC, Xavier SG, Souza ME de L, Murao M, de

Oliveira BM. Comparison between flow cytometry and

standard PCR in the evaluation of MRD in children with

acute lymphoblastic leukemia treated with the GBTLI

LLA–2009 protocol. Pediatr Hematol Oncol [Internet].

;36(5):287–301. Available from: https://doi.org/10.10

/08880018.2019.1636168

Rytting ME, Jabbour EJ, O’Brien SM, Kantarjian HM.

Acute lymphoblastic leukemia in adolescents and young

adults. Cancer [Internet]. 2017;123(13):2398–403.

Available from: https://acsjournals.onlinelibrary.wiley.com/

doi/full/10.1002/cncr.30624

Ministerio de salud y Protección Social. Guía de práctica

clínica para la detección, tratamiento y seguimiento de

leucemias linfoblásticas y mieliode en población mayor

de 18 años [Internet]. Vol. 126, Circulation. 2017. 37

p. Available from: http://gpc.minsalud.gov.co/gpc_sites/

Repositorio/Conv_563/GPC_Leucemia_Mayores_18años/

LEUCEMIAS - profesionalesDIC29_WEB.pdf

Keegan A, Charest K, Schmidt R, Briggs D, Deangelo

DJ, Li B, et al. Flow cytometric minimal residual disease

assessment of peripheral blood in acute lymphoblastic

leukaemia patients has potential for early detection of

relapsed extramedullary disease. J Clin Pathol [Internet].

;1–6. Available from: https://jcp.bmj.com/

content/71/7/653

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C,

Garnache-Ottou F, et al. Methodological aspects of minimal

residual disease assessment by flow cytometry in acute

lymphoblastic leukemia: A french multicenter study. Cytom

Part B - Clin Cytom [Internet]. 2015;88(1):21–9. Available

from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/

cyto.b.21195

Thulasi Raman R, Anurekha M, Lakshman

V, Balasubramaniam R, Ramya U, Revathi R.

Immunophenotypic modulation in pediatric B

lymphoblastic leukemia and its implications in MRD

detection. Leuk Lymphoma [Internet]. 2020;61(8):1974–

Available from: https://doi.org/10.1080/10428194.202

1742902

Ravandi F, Jorgensen JL, O’Brien SM, Jabbour E, Thomas

DA, Borthakur G, et al. Minimal residual disease assessed

by multi-parameter flow cytometry is highly prognostic

in adult patients with acute lymphoblastic leukaemia. Br

J Haematol [Internet]. 2016;172(3):392–400. Available

from: https://onlinelibrary.wiley.com/doi/full/10.1111/

bjh.13834

Li HF, Meng WT, Jia YQ, Jiang NG, Zeng TT, Jin YM, et

al. Development-Associated immunophenotypes reveal the

heterogeneous and individualized early responses of adult

B-Acute lymphoblastic leukemia. Med (United States)

[Internet]. 2016;95(34). Available from: https://journals.

lww.com/md-journal/Fulltext/2016/08230/Development_

associated_immunophenotypes_reveal_the.18.aspx

Li SQ, Fan QZ, Xu LP, Wang Y, Zhang XH, Chen H, et al.

Different Effects of Pre-transplantation Measurable Residual

Disease on Outcomes According to Transplant Modality

in Patients With Philadelphia Chromosome Positive ALL.

Front Oncol [Internet]. 2020;10(March):1–13. Available

from: https://www.frontiersin.org/articles/10.3389/

fonc.2020.00320/full

Keeney M, Hedley BD, Chin-Yee IH. Flow cytometry—

Recognizing unusual populations in leukemia and

lymphoma diagnosis. Int J Lab Hematol [Internet].

;39(January):86–92. Available from: https://

onlinelibrary.wiley.com/doi/full/10.1111/ijlh.12666

Marsán Suárez V, del Valle Pérez LO, Díaz Domínguez

G, Macías Abraham C. Metodología y aplicaciones de

la citometría de flujo para el inmunofenotipaje de las

leucemias agudas Methodology and applications of flow

cytometry for immunophenotyping of acute leukemias.

Rev Cuba Hematol, Inmunol y Hemoter [Internet].

;31(3):242–53. Available from: http://scielo.sld.cu

Wood BL. Principles of minimal residual disease detection

for hematopoietic neoplasms by flow cytometry. Cytom Part

B - Clin Cytom [Internet]. 2016;90(1):47–53. Available

from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/

cyto.b.21239

Theunissen P, Mejstrikova E, Sedek L, Van Der Sluijs-

Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow

cytometry for highly sensitive MRD measurements in

B-cell acute lymphoblastic leukemia. Blood [Internet].

;129(3):347–57. Available from: https://

ashpublications.org/blood/article/129/3/347/36021/

Standardized-flow-cytometry-for-highly-sensitive

Arriaga-Pizano L, Ramírez-Ramírez D, Prieto-Chávez

J, Pelayo R, Ruiz-Argüelles A. Report of the First

National Consensus Meeting for Acute Leukemias

Immunophenotyping. Gac México [Internet].

;155(1):4–10. Available from: https://www.

gacetamedicademexico.com/frame_esp.php?id=245

Consorcio EuroFlow. Standardized EuroFlow Protocols.

EuroFlow [Internet]. 2018;1. Available from: https://

euroflow.org/protocols/

Cytognos SL. BulklysisTM Para uso diagnóstico in vitro.

Cytognos [Internet]. 2022;1. Available from: https://www.

cytognos.com/products/cyt-bl/

Kalina T, Velden VHJ Van Der, Bo S. EuroFlow

standardization of flow cytometer instrument

settings and immunophenotyping protocols.

;(January):1986–2010. Available from: https://www.

nature.com/articles/leu2012122

Chatterjee T, Mallhi RS, Venkatesan S. Minimal residual

disease detection using flow cytometry: Applications in

acute Leukemia. Med J Armed Forces India [Internet].

;72(2):152–6. Available from: http://dx.doi.

org/10.1016/j.mjafi.2016.02.002

Chen X, Wood BL. Monitoring minimal residual disease

in acute leukemia: Technical challenges and interpretive

complexities. Blood Rev [Internet]. 2017;31(2):63–

Available from: http://dx.doi.org/10.1016/j.

blre.2016.09.006

Wenzinger C, Williams E, Gru AA. Updates in the

Pathology of Precursor Lymphoid Neoplasms in the Revised

Fourth Edition of the WHO Classification of Tumors of

Hematopoietic and Lymphoid Tissues. Curr Hematol Malig

Rep [Internet]. 2018;13(4):275–88. Available from: https://

link.springer.com/article/10.1007/s11899-018-0456-8

Xia M, Zhang H, Lu Z, Gao Y, Liao X, Li H. Key

markers of minimal residual disease in childhood acute

lymphoblastic leukemia. J Pediatr Hematol Oncol

[Internet]. 2016;38(6):418–22. Available from: https://

journals.lww.com/jpho-online/Abstract/2016/08000/Key_

Markers_of_Minimal_Residual_Disease_in.2.aspx

Popov A, Henze G, Verzhbitskaya T, Roumiantseva J,

Lagoyko S, Khlebnikova O, et al. Absolute count of

leukemic blasts in cerebrospinal fluid as detected by flow

cytometry is a relevant prognostic factor in children with

acute lymphoblastic leukemia. J Cancer Res Clin Oncol

[Internet]. 2019;145(5):1331–9. Available from: http://

dx.doi.org/10.1007/s00432-019-02886-3

McShane LM, Smith MA. Prospects for Minimal Residual

Disease as a Surrogate Endpoint in Pediatric Acute

Lymphoblastic Leukemia Clinical Trials. JNCI Cancer

Spectr [Internet]. 2018;2(4):5–6. Available from: https://

academic.oup.com/jncics/article/2/4/pky070/5253647

Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G,

Buldini B, et al. Minimal residual disease analysis by

eight-color flow cytometry in relapsed childhood acute

lymphoblastic leukemia. Haematologica [Internet].

;100(7):935–44. Available from: https://

haematologica.org/article/view/7439

Bruggemann M, Kotrova M. Minimal residual disease

in adult ALL: Technical aspects and implications for

correct clinical interpretation. Blood Adv [Internet].

;1(25):2456–66. Available from: https://

ashpublications.org/hematology/article/2017/1/13/21072/

Minimal-residual-disease-in-adult-ALL-technical

Walter RB, Gooley TA, Wood BL, Milano F, Fang M,

Sorror ML, et al. Impact of pretransplantation minimal

residual disease, as detected by multiparametric flow

cytometry, on outcome of myeloablative hematopoietic cell

transplantation for acute myeloid leukemia. J Clin Oncol

[Internet]. 2011;29(9):1190–7. Available from: https://

www.hindawi.com/journals/lrt/2014/421723/

Gökbuget N. How should we treat a patient with

relapsed Ph-negative B-ALL and what novel approaches

are being investigated? Best Pract Res Clin Haematol

[Internet]. 2017;30(3):261–74. Available from:

https://www.sciencedirect.com/science/article/abs/pii/

S1521692617300270?via%3Dihub

Tembhare PR, Narula G, Khanka T, Ghogale S, Chatterjee

G, Patkar N V., et al. Post-induction Measurable Residual

Disease Using Multicolor Flow Cytometry Is Strongly

Predictive of Inferior Clinical Outcome in the Real-Life

Management of Childhood T-Cell Acute Lymphoblastic

Leukemia: A Study of 256 Patients. Front Oncol [Internet].

;10(April):1–13. Available from: https://www.

frontiersin.org/articles/10.3389/fonc.2020.00577/full

Schrappe M. Detection and management of minimal

residual disease in acute lymphoblastic leukemia.

Hematol (United States) [Internet]. 2014;2014(1):244–9.

Available from: https://ashpublications.org/hematology/

article/2014/1/244/20518/Detection-and-management-ofminimal-

residual

Kruse A, Abdel-Azim N, Kim HN, Ruan Y, Phan V,

Ogana H, et al. Minimal residual disease detection in

acute lymphoblastic leukemia. Int J Mol Sci [Internet].

;21(3). Available from: https://www.mdpi.com/1422-

/21/3/1054/htm

Abou Dalle I, Jabbour E, Short NJ. Evaluation and

management of measurable residual disease in acute

lymphoblastic leukemia. Ther Adv Hematol [Internet].

;11:204062072091002. Available from: https://

journals.sagepub.com/doi/10.1177/2040620720910023

Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera

JM, Buske C, et al. Acute lymphoblastic leukaemia in

adult patients: ESMO clinical practice guidelines for

diagnosis, treatment and follow-up. Ann Oncol [Internet].

;27(February):v69–82. Available from: http://dx.doi.

org/10.1093/annonc/mdw025

Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S,

Cheng C, et al. Clinical impact of minimal residual disease

in children with different subtypes of acute lymphoblastic

leukemia treated with Response-Adapted therapy. Leukemia

[Internet]. 2017;31(2):333–9. Available from: http://dx.doi.

org/10.1038/leu.2016.234

Campana D, Pui C. Evidence-Based Focused Review

Minimal residual disease – guided therapy in childhood

acute lymphoblastic leukemia Case presentations. Blood

[Internet]. 2017;129(14):1913–9. Available from: https://

ashpublications.org/blood/article/129/14/1913/35887/

Minimal-residual-disease-guided-therapy-in

Jabbour E, O’Brien S, Konopleva M, Kantarjian H.

New insights into the pathophysiology and therapy of

adult acute lymphoblastic leukemia. Cancer [Internet].

;121(15):2517–28. Available from: https://acsjournals.

onlinelibrary.wiley.com/doi/full/10.1002/cncr.29383

Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia.

Hematology [Internet]. 2016 Dec 2;2016(1):580–8.

Available from: https://ashpublications.org/hematology/

article/2016/1/580/21136/T-cell-acute-lymphoblasticleukemia

Nováková M, Glier H, Brdičková N, Vlková M, Helena

A, Lima M, et al. How to make usage of the standardized

EuroFlow 8-color protocols possible for instruments of

different manufacturers. J Immunol Methods [Internet].

;475. Available from: https://ezproxy.unicolmayor.edu.

co:2163/science/article/pii/S0022175917301394

PETHEMA. Protocolo para el tratamiento de la leucemia

aguda linfoblastica de alto riesgo bcr/abl negativa en

adultos. Soc ESPAÑOLA Hematol Y Hemoter. 2013;1–46.

Euroflow and Cytognos. CYT-BCP-ALL-MRD, B-Cell

Precursor Acute Lymphoblastic Leukemia Minimal Residual

Disease. 2022;3:1–7. Available from: https://www.cytognos.

com/products/cyt-bcp-all-mrd/

Euroflow and Cytognos. CYT-ALOT Acute Leukemia

Orientation Tube. Cytognos [Internet]. 2022;3:1–9.

Available from: https://www.cytognos.com/products/cytalot/

Theunissen PMJ, Sedek L, Haas V De, Szczepanski T, Der

A Van, Mejstrikova E, et al. Detailed immunophenotyping

of B-cell precursors in regenerating bone marrow of acute

lymphoblastic leukaemia patients : implications for minimal

residual disease detection. Br J Haematol [Internet].

;178(2):257–66. Available from: https://onlinelibrary.

wiley.com/doi/10.1111/bjh.14682

Cytognos SL. Cytognos Products. Cytognos. Cytognos.

;(3):1–4.